Physician profile
Babar Ahmad
NPI 1619081684
$1,212.02
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2021: $488 · 2022: $150 · 2023: $149 · 2024: $61.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $210.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $260.62 | 2019-2024 | |
| Welch Allyn | $191.60 | 2021 | |
| Astellas Pharma US INC | $99.95 | 2021 | |
| Pfizer INC. | $96.86 | 2019-2023 | |
| Novo Nordisk INC | $78.65 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.85 | 2019-2022 | |
| Glaxosmithkline, LLC. | $45.91 | 2021-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $38.10 | 2022-2023 | Opsumit, Uptravi |
| Lilly USA, LLC | $34.02 | 2021 | |
| Nestle Healthcare Nutrition INC. | $28.48 | 2023 | |
| Insulet Corporation | $28.28 | 2019 | |
| Alexion Pharmaceuticals, INC. | $23.32 | 2022 | |
| Merck Sharp & Dohme LLC | $22.48 | 2019 | |
| Clarus Therapeutics INC. | $19.84 | 2021 | |
| Nevro Corp. | $19.02 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $15.61 | 2022 | |
| Allergan, INC. | $15.38 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.61 | 2021 | |
| Amarin Pharma, INC. | $13.88 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.76 | 2023 | Rexulti |
| Acadia Pharmaceuticals INC | $13.30 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.29 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.69 | 2021 | |
| Amgen INC. | $12.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.13 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $12.09 | 2021 | |
| Daiichi Sankyo INC. | $11.71 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babar Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.